Fresh from unveiling a $3.1B fund, New Enterprise Associates is the sole investor in a $3 million Series A round by MORE Health. The health IT startup wants to connect Chinese doctors and their patients with U.S. specialists across areas such as oncology, neurology, cardiology and pediatrics. As part of its investment, Xiaodong Jiang, managing […]
Looks like NEA will invest about $1 billion in healthcare startups over the next few years. Areas like immuno-oncology, electrophysiology and
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Venture firm New Enterprise Associates made some massive waves today on news that it’s closed its fifteenth – and largest – fund, which holds $3.1 billion. And a huge swath of that – 30 to 40 percent, according to Fierce – could likely be allocated to the healthcare space. MedCity News reported initially on NEA’s plans to raise funds – it filed […]
New Enterprise Associates, a prodigious venture investor in healthcare across biotech, medical devices and healthcare services, is raising a $2.5 billion fund, according to an SEC document. If its previous funds are anything to go by, it could be its largest fund to date. It currently invests in a total of 96 companies in the […]
In yet another example of industry’s growing interest in orphan drugs, a small Texas startup secured an impressive Series A to ramp up its work on a treatment for a rare disease called CTD. Life science investors Sante Ventures and New Enterprise Associates co-led the $14 million Series A for Lumos Pharma, which is repurposing […]
At Advamed 2013, industry leaders met and discussed how startups and innovation can beat the odds without much chance of gaining venture capital at an extremely early stage. Here are realistic options for medical device companies looking to fundraise early rounds without venture. 1. Raise enough for each round. Remember that truism from Mark Twain […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
CVRx, a Minneapolis-based firm that has developed proprietary implantable technology for the treatment of high blood pressure and heart failure, has raised $29.6 million for advancing clinical trials of its Barostim Neo, as well as expanding commercial activities abroad. Johnson & Johnson Development Corp. and New Enterprise Associates, Inc. were the co-lead investors. According to […]
As investments in life science companies have dipped over the past few years, some investors have scaled back investments or walked away from the sector all together. But based on a tally by investment research firm PitchBook in its 2013 Venture Capital Healthcare Report, several firms have made 10 or more investments in pharmaceutical, medical […]
Denis Harrington, who until recently was head of sales for Boston Scientific Corp.'s cardiovascular and CRM business, has left the company to become president and CEO of a Twin Cities startup called BridgePoint Medical Inc.
The CED Biotech/Life Science Conference didn’t have an official theme, but if it did, it could have been "think early." What the more than 1,000 in attendance got was a steady, instructional drumbeat telling them to think about facing important decisions for their companies and their research and development at earlier stages than they’re accustomed.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
BridgePoint Medical Inc. has raised $9.1 million from the sale of equity. The company based in Plymouth, Minnesota, is developing balloon catheter system to treat chronic coronary and peripheral total occlusions, a condition in which clots frequently clog blood vessels.
The Philadelphia-area pharmaceutical company hopes for medical breakthroughs in Type 2 diabetes and hypertension. PhaseBio has embarked on Phase I and Phase II testing of its diabetes treatment, Glymera. Another treatment, Vasomera, focuses on hypertension. The $15 million was part of a total $25 million raised by the former Research Triangle Park/Duke University spinoff.
BridgePoint Medical Inc. has raised $1 million from the sale of debt and stock warrants, according to documents filed with the Securities and Exchange Commission. The company, based in Plymouth, Minnesota, is developing balloon catheter system to treat chronic coronary and peripheral total occlusions, a condition in which clots frequently clog blood vessels. Last year, […]
Acorn Cardiovascular Inc., which has struggled for years to convince the Food and Drug Administration to approve its heart device, will need to either raise more money or sell the company, MedCity News has learned. In an e-mail, Acorn president Steve Anderson said the company already has slashed costs, including shutting down its website and moving out of its headquarters in New Brighton, Minnesota.
Trevena Inc. has landed a sizable $35 million Series B round that it hopes will push its lead heart-failure drug through Phase 2 clinical trials. The funding was led by venture heavyweights and existing investors Polaris Venture Partners and New Enterprise Associates. Other previous investors — Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company […]